Federal Science and Technology Grants

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Level 4. Funding Levels 1, 2, and 3 are available under other program announcements (HT942524BCRPBTA12 for Levels 1 and 2 and HT942524BCRPBTA3 for Level 3). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcements before submitting the pre-application. An application that does not meet the intent of Funding Level 4 will not be recommended for funding, even if it might meet the intent of a different funding level.The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement:Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required. Large-scale trials, such as comparative effectiveness clinical trials, that will transform and revolutionize the clinical management and/or prevention of breast cancer and lead to unprecedented impact on patients lives, may fall under this mechanism. PIs are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical trial successfully. Where relevant, applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or critical reagents. For proposed research that will require U.S. Food and Drug Administration (FDA) involvement, project readiness requirements at the time of application submission include: proof of availability of and access to clinical reagents (e.g., therapeutics) that meet regulatory compliance guidelines, proof of availability of and access to appropriate subject population(s), validated projections for patient recruitment, and submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the FDA, if applicable.Funding from this award mechanism must support a clinical trial. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Note: An invited oral presentation is a requirement for application review of Funding Level 4 projects, as described in Section II.D.2.b, Full Application Submission Content.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Level 4 applications unless they are clearly addressing distinct research questions. Applications where one PI is providing samples or investigational agents while the other PI is performing most or all of the research and analyses do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project.Key Aspects of the BCRP Breakthrough Award Level 4 Mechanism: Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of FDA processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312), Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international regulatory agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant regulatory agency by the Breakthrough Award Level 4 application submission deadline. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency by the Breakthrough Award Level 4 application submission deadline. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The types of awards made under the program announcement will be cooperative agreements (31 USC 6305) based on anticipated substantial involvement on the part of CDMRP. Substantial involvement includes assistance, guidance, coordination, and/or participation by CDMRP staff in project activities, including but not limited to, Milestone Meetings wherein recommendations for continued funding will be made based on overall study progress.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP BTA4 should not exceed $15M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $23.3M to fund approximately one Breakthrough Award Level 4 application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Public Diplomacy Section (PD) of the U.S. Embassy in Luxembourg, U.S. Department of State, announces an open competition for organizations to submit applications to carry out programs strengthening bilateral ties between the United States and Luxembourg on Accelerating STEM and Climate Ambitions. The U.S. Embassy Luxembourg invites proposals from non-governmental organizations, think tanks, government institutions, academic institutions, and individuals for programs strengthening the bilateral ties between the United States and Luxembourg and Accelerating STEM and Climate Ambitions, including, but not limited to: Programs that raise awareness about space and satellite technology, space exploration, biotechnology, green technology, clean energy, climate change, the climate crisis, or sustainable finance. This could include educational programs for young people, trainings for educators, public debates, exhibits, speakers, etc. Educational programs with a focus on interactive STEM skills, such as computer programming, coding, and robotics, or programs about the importance of protecting the environment, clean air and water and sustainability measures. Projects that share American best practices in STEM and space research, climate change, sustainability, sustainable finance, renewables, environmental protection, or biotechnology by bringing U.S. experts to engage with Luxembourg audiences. All programs must engage Luxembourg audiences. All programs must include a U.S. element or connection with U.S. experts that will promote increased understanding of U.S. policy and perspectives. Any speaker paid with grant funding must hold U.S. citizenship. Please review the complete NOFO on the Funding Opportunities page on our website: https://lu.usembassy.gov/grants-program/ , or in the related documents tab on the announcement on grants.gov.

This competition provides funding and flight testing opportunities for U.S.-based individuals, teams, and organizations to develop innovative space technologies that address critical challenges identified by NASA.

The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals in the development of highly coherent sources of vacuum ultraviolet (VUV) radiation for clock-grade spectroscopy of the recently discovered thorium (229m-Th) nuclear isomeric transition. Proposed research should investigate innovative approaches that enable revolutionary advances in science, devices, or systems. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

The DOD Traumatic Brain Injury and Psychological Health, Emerging Topics Research Award aims to accelerate research in traumatic brain injury and psychological health, with the goal of developing new clinical applications, health care products, and guidelines for Service Members, their Families, Veterans, and the American public.

The "Request for Information (RFI) - Engineering Solutions to Harvest Biomass Carbon for Durable Removal and Storage (Carbon Harvesting)" grant is seeking ideas for a potential future program that aims to develop innovative technologies to enhance the energy efficiency of carbon dioxide removal, using photosynthesis, to help achieve the U.S. net zero targets by reducing the energy demand of carbon removal processes.

This funding opportunity supports two established melanoma researchers to co-lead a virtual network that mentors and develops early-career melanoma researchers through collaborative initiatives and professional growth.

This funding opportunity provides financial support for U.S. and Jordanian organizations to create public programs that celebrate American history, culture, and civic values, fostering collaboration and engagement between communities in both countries.

This funding opportunity provides financial support for designated federal, state, tribal, and academic partners to conduct research and data collection that promotes sustainable management of natural resources and environmental studies.

The "DoD Rare Cancers, Idea Development Award" is a grant aimed at supporting early-stage research ideas with high potential impact, which could lead to significant advancements in the diagnosis, treatment, and improved health outcomes for individuals suffering from rare cancers, with a particular focus on innovative research involving nuclear medicine, women's health, and adherence to rigorous study design standards.

The NNSA Academic Programs and Community Support, Office of Advanced Simulation and Computing (ASC) and Institutional Research and Development Programs (NA-114), Lawrence Livermore National Laboratory (LLNL), Los Alamos National Laboratory (LANL) and Sandia National Laboratories (SNL), are initiating the next phase of its academic program, called Predictive Science Academic Alliance Program IV (PSAAP IV). PSAAP IV will add an additional focus, on the development and application of artificial intelligence (AI) and machine learning (ML) technologies to improve quantified predictive capabilities. The DOE NNSA Academic Programs and Community Support PSAAP IV Notice of Funding Opportunity (NOFO), DE-FOA-NA0003284, and succeeding awarded agreements, are made possible from NNSAs statutory authority, and are managed by applicable guidance, regulations, and laws. Predictive Science Academic Alliance Program IV (PSAAP IV) will support leading U.S. institutions of higher education, with doctoral programs, engaging in five major focus areas: 1. Discipline-focused research to further predictive science and enabled by effective exascale computing and data science technologies; 2. Mathematics and computer science (CS) technologies and methodologies to support effective exascale computing in the context of science/engineering applications (development and demonstration); 3. State-of-the-art machine learning (ML) and data science technologies for predictive science and engineering (utilization and advancement); 4. Predictive science based on verification, validation, and uncertainty quantification (VVUQ) for large-scale simulations; and 5. Workforce development of the next-generation computational scientists. PSAAP IV will create a program consisting of two types of Centers: Predictive Simulation Centers (PSCs) and Focused Investigatory Centers (FICs). 1. Predictive Simulation Centers (PSCs) will be required to focus their research on scalable application simulations, targeting either large-scale, integrated multidisciplinary problems or a broad single science/engineering discipline, to be carried out on ASCs unclassified high-performance computing (HPC) systems that will be made available to the funded PSAAP IV Centers. A PSC must (1) develop and demonstrate computer and/or data science technologies and methodologies that will advance exascale computing, and (2) demonstrate a verified and validated predictive simulation (or simulation-driven workflow) with uncertainty quantification. Both (1) and (2) must be demonstrated within the context of the proposed application. It is expected that a PSC will demonstrate a compelling and significant advance in predictive science, in the context of their application. The overall goal should require the integration of state-of-the-art techniques and advances in physical science, scientific machine learning, and exascale-enabled computer/computational science to demonstrate improved predictive capability. This should be manifested as predictions of a wider range of phenomena, with improved predictive accuracy and reduced uncertainty, in comparison to existing capabilities at the beginning of the project. Integrated system simulation (or simulation-driven workflow) results for a single demonstration problem must be produced each year, beginning in the second year of the program. All research efforts within a PSC must contribute towards advancing this predictive capability and be integrated no later than the year 4 demonstration. It is anticipated that PSCs will be 5-year awards at $1.5-3.5M per year, with the larger-award sizes for Centers targeting multidisciplinary problems and advancing both CS and ML technologies. 2. Focused Investigatory Centers (FICs) will be required to be tightly focused on a specific research topic either in one of the disciplines or one or more of the exascale-enabling CS, ML, or VVUQ technologies listed below. FICs will not necessarily have a tie to an application or be required to demonstrate a verified, validated predictive simulation with uncertainty quantification. Successful FIC will demonstrate a compelling and significant scientific advance in the single discipline or enabling technology. The technical advance should represent a qualitative step up in the discipline, as opposed to incremental progress. It is anticipated that FIC awards will be up to 5-year awards, at $0.5-1.0M per year. DOE/NNSA will award cooperative agreements under this NOFO. DOE/NNSA will consider funding multi-institution teams submitted as a prime and subaward model with one application submitted by the lead institution (prime applicant). Approximately $20,000,000 annually is anticipated to be available for awards under this NOFO. Funding for all awards and future budget periods are contingent upon the availability of funds appropriated by Congress for the purpose of this program and the availability of future-year budget authority. Grants.gov Questions Direct questions relating to the Grants.gov registration process, system requirements, application form, or the submittal process must be directed to Grants.gov at 1-800-518-4726 or support@Grants.gov. DOE/NNSA staff are unable to answer Grants.gov questions. NOFO Questions Direct specific program and technical questions through FedConnect found at FedConnect - Gateway to Government Opportunities. Responses to FAQs will be posted periodically via FedConnect to registered applicants. Responses to FAQs will also be posted to the PSAAP IV FAQs website at PSAAP-IV NOFO FAQ PSAAP (llnl.gov)

This funding opportunity supports innovative research aimed at preventing Alzheimer’s disease and related dementias, particularly in relation to military service and traumatic brain injury, targeting independent researchers from various eligible organizations.

The U.S. Department of Justice (DOJ), Office of Justice Programs (OJP), National Institute of Justice (NIJ) is seeking applications for funding. OJP is committed to advancing work that promotes civil rights and equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety and protects the public from crime and evolving threats, and builds trust between law enforcement and the community. With this solicitation, NIJ seeks proposals for rigorous applied research and evaluative studies on innovations, initiatives, and strategies in both institutional and community corrections. This program furthers DOJs mission to uphold the rule of law, to keep our country safe, and to protect civil rights.

With this solicitation, NIJ seeks to continue funding to support the Law Enforcement Advancing Data and Science (LEADS) Scholars Program, an ongoing NIJ program designed to increase the in-house research capabilities of law enforcement agencies by building data and research skills of individuals employed by and engaged with these agencies.

This initiative seeks input from various stakeholders, including businesses, researchers, and government entities, to enhance the recycling and reuse of products and materials, ultimately promoting environmental sustainability and economic resilience.

This funding opportunity supports U.S. and Canadian organizations in creating public diplomacy projects that foster mutual understanding and cooperation between the two countries, focusing on shared interests like innovation, security, and cultural exchange.

The U.S. National Science Foundations Directorate for Technology, Innovation and Partnerships (TIP) is charged with accelerating use-inspiredand translationalresearch and development (R) to advance U.S. competitiveness in key technology focus areas. The Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (CFIRE) initiative will accelerate the adoption of cell-free systems, enable new applications of this technology and contribute to the growth of the U.S. bioeconomy. A nascent industry has formed around the ability to carry out biochemical processes, such as DNA transcription/translation, in cell-free in-vitro systems instead of in traditional cell-based in-vivo bio-reactors. This approach has a number of potential advantages, including rapid turn-around, distributed and highly retargetable manufacturing, high-fidelity instrumentation and control of the manufacturing environments without the constraints of biological growth and the interference caused by cell biomass and cell membranes during product purification. Furthermore, cell-free systems can produce products that are challenging to manufacture in cell-based cultures, such as those inherently toxic to cells or hydrocarbon products that are consumed by the cellular machinery. Despite these advantages, present-day cell-free manufacturing is significantly more expensive than cell-based methods and cell-free systems have a limited range of applications. CFIRE aims to: 1. Reduce the cost of cell-free systems; 2. Increase the range and capabilities of cell-free systems; and 3. Develop and demonstrate cost-effective use-inspired applications. CFIRE will address the key limitations of cell-free technology by identifying technical approaches that can enable ongoing cycles of improvement. The objective is to place cell-free technology on an exponential growth path in which reduced costs lead to increasing adoption which, in turn, generates the learning and investment required to further reduce costs. In order to keep the work focused and to stimulate increasing adoption, efforts funded through this initiative will focus on one or more specific use cases. CFIRE seeks significant breakthroughs that will accelerate the adoption of cell-free systems by: (a) Demonstrating the feasibility and advantages of cell-free systems through use-inspired applications with specific emphasis on applications beyond human therapeutics; (b) Creating infrastructure components, such as tools, protocols, kits, datasets, and characterization services that can readily be accessed by third parties; and (c) Investing in workforce components focused on the training of translational talent with the skills and passion to engage in use-driven cell-free applications. CFIRE will use the Ideas Lab process (see PAPPG Chapter II.F.6), starting with an intensive meeting that brings together multiple diverse perspectives. The primary objectives of this Ideas Lab workshop will be to: identify specific opportunities to significantly reduce the cost of cell-free systems; establish acceptable standards for the fidelity and reproducibility; expand the range of capabilities in order to facilitate broader adoption of the technology; and identify and prioritize use-driven applications beyond human therapeutics.

This grant provides funding for research organizations and educational institutions to study the ecological and evolutionary factors influencing the spread of infectious diseases, particularly in low- and middle-income countries.

Please note that this program requests optional Notices of Intent, which are due via NSPIRES by March 28, 2024. See the full posting on NSPIRES for details. Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

This funding opportunity provides financial support for research projects focused on forest management and ecosystem health in the Upper Mississippi River System, targeting non-federal partners with expertise in floodplain ecosystems.